company background image
SONN logo

Sonnet BioTherapeutics Holdings NasdaqCM:SONN Stock Report

Last Price

US$1.56

Market Cap

US$4.8m

7D

-13.8%

1Y

-89.1%

Updated

20 Dec, 2024

Data

Company Financials +

Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM:SONN Stock Report

Market Cap: US$4.8m

SONN Stock Overview

A biotechnology company, owns a platform for biologic medicines of single or bifunctional action. More details

SONN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Sonnet BioTherapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sonnet BioTherapeutics Holdings
Historical stock prices
Current Share PriceUS$1.56
52 Week HighUS$18.72
52 Week LowUS$1.55
Beta0.91
1 Month Change-46.58%
3 Month Change-80.50%
1 Year Change-89.11%
3 Year Change-99.86%
5 Year Changen/a
Change since IPO-99.99%

Recent News & Updates

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

Shareholder Returns

SONNUS BiotechsUS Market
7D-13.8%-3.6%-2.4%
1Y-89.1%-2.7%23.3%

Return vs Industry: SONN underperformed the US Biotechs industry which returned -1.5% over the past year.

Return vs Market: SONN underperformed the US Market which returned 22.1% over the past year.

Price Volatility

Is SONN's price volatile compared to industry and market?
SONN volatility
SONN Average Weekly Movement16.5%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SONN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SONN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a13Pankaj Mohanwww.sonnetbio.com

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.

Sonnet BioTherapeutics Holdings, Inc. Fundamentals Summary

How do Sonnet BioTherapeutics Holdings's earnings and revenue compare to its market cap?
SONN fundamental statistics
Market capUS$4.78m
Earnings (TTM)-US$7.44m
Revenue (TTM)US$18.63k

251.9x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SONN income statement (TTM)
RevenueUS$18.63k
Cost of RevenueUS$109.36k
Gross Profit-US$90.73k
Other ExpensesUS$7.35m
Earnings-US$7.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.47
Gross Margin-487.11%
Net Profit Margin-39,929.30%
Debt/Equity Ratio0%

How did SONN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sonnet BioTherapeutics Holdings, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Michael KingH.C. Wainwright & Co.